Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Raltitrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS known ✓ | P04818 | 8/20 | 1.00 |
| ▸ | DHFR | P00374 | 1/20 | 1.00 |
| ▸ | FOLR2 | P14207 | 1/20 | 1.00 |
| ▸ | FOLR1 | P15328 | 1/20 | 1.00 |
| ▸ | SLC19A1 | P41440 | 1/20 | 1.00 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 1.00 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raltitrexed SCHEMBL7438 | 1.00 | TYMS (1.00) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL6240639 | 1.00 | TYMS (1.00) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL12078376 | 1.00 | TYMS (1.00) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL13959 | 1.00 | TYMS (1.00) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL27995440 | 0.99 | TYMS (0.98) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL28154699 | 0.99 | TYMS (0.98) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL16583752 | 0.99 | TYMS (0.98) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL28384446 | 0.99 | TYMS (0.98) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL21248507 | 0.99 | TYMS (0.98) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL28155448 | 0.99 | TYMS (0.98) | TYMSDHFRFOLR2FOLR1SLC19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4646411-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646413-A1 | SOLID FORMS OF A CDK2 INHIBITOR | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646416-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646414-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025227007-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250213476-A1 | GAMMA POLYGLUTAMATED RALTITREXED AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-07-03 | — | — | US | disclosed |
| US-20250213567-A1 | ALPHA POLYGLUTAMATED RALTITREXED AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-07-03 | — | — | US | disclosed |
| WO-2025054386-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-4355742-A1 | SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-04-24 | — | — | EP | disclosed |
| CN-117813300-A | Substituted pyrimidinyl-pyrazoles as CDK2 inhibitors | 缆图药品公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023092088-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023092107-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023278326-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022266190-A1 | SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-4013404-A1 | METHODS OF TREATING CANCER | F. Hoffmann-La Roche AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| EP-3986890-A1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114209841-A | Therapeutic compositions, combinations and methods of use | 维瑞斯特姆股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114222576-A | Methods of treating cancer | F·霍夫曼-罗氏股份公司 | 2022-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213476-A1 | GAMMA POLYGLUTAMATED RALTITREXED AND USES THEREOF | GGCT, IFNG, RARG | TYMS 76/4885DHFR 45/4885FOLR2 35/4885 |
| US-20250213567-A1 | ALPHA POLYGLUTAMATED RALTITREXED AND USES THEREOF | GGCT, RARS1, RARG | TYMS 152/4885DHFR 159/4885FOLR2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.